Immunwork, Inc. founded in 2014, focuses on the research, development, and commercialization of a series of novel drugs to fulfill unmet medical needs. Our novel “T-E” drug candidates, containing targeting (T) and effector (E) moieties, are created by proprietary “Multi-Arm Linker” platform for treating multiple types of cancer, diabetes, non-alcoholic steatohepatitis (NASH), obesity and pathological blood clots. According to our innovative “Multi-Arm Linker” platform design, we use an enzyme-free click reaction to generate homogeneous antibody-drug conjugates (ADCs) or antibody-radionuclide conjugates (ARCs) with site-specific conjugation, high drug-to-antibody ratio (DAR), high reaction yield and high purity. Furthermore, the platform can also be employed for constructing ultra-long-acting peptide drugs, we conjugate two or more fatty acids on one specific residue to optimize the PK/PD profile and reduce the dosing frequency. Meanwhile, we are expecting to apply the platform for designing additional novel drug candidates.
Until now, six drug candidates have been progressed into the pre-clinical stage, including TE-8214, TE-1132 and TE-1146 for treating oncology, TE-8035 for treating diabetes, TE-8105 for treating type II diabetes, obesity and NASH and TE-6168 for treating pathological clots. The two lead product candidates, TE-8105 and TE-8214 are scheduled for IND filing in 2024. In addition, ADC/ARC platforms and their product assets, TE-1146 and TE-1132 have authorized to T-E Meds, Inc., the affiliated company of Immunwork, to perform further development.
|2014||Immunwork, Inc. was founded in October 2014.|
|2019||After a corporate reorganization in November 2019, Immunwork is now a wholly owned subsidiary of T-E Pharma Holding, incorporated in Cayman Island.|
|2021||T-E Pharma Holding (TEPH) is to issue common shares for raising.|
|2021||TE-8105 is recognized by CDE as Index Case|
|2022||The affiliated company, T-E Meds, Inc. was founded in November 2022.|